Biosimilars Market Size To Reach $151.58 Million By 2033

October 2025 | Report Format: Electronic (PDF)

Biosimilars Market Growth & Trends

The global biosimilars market size is expected to reach USD 151.58 million by 2033, registering a CAGR of 18.27% from 2025 to 2033, according to a new report by Grand View Research, Inc. The growth of this market can be attributed to their cost effectiveness for both patients & manufacturers and the increasing prevalence of chronic & non-communicable diseases, such as cancer and anemia. According to the World Health Organizationestimates, 40% of children below five years of age, and 30% of women between the age group of 15 and 49 years are suffering from anemia. Moreover, biosimilar drugs offer almost similar results and are considered a more affordable alternative to their reference biologics.

Since they are almost similar, the producers of biologics also have to lower their prices to compete with biosimilars, which reduce the cost of the overall treatment. For instance, a report published by Biosimilars Forum in April 2021 suggests that increasing competition from biosimilars has resulted in lowering the prices of biologics by an average of 56% to up to 150%. Furthermore, biologics have patents to protect them from competing with biosimilars. These patents restrict the production of biosimilars for a period of 8 to 20 years depending on the regulations in different countries. However, patents of many lifesaving biologics are expected to expire during the forecast period, which can boost growth.

According to an article by Congressional Budget Office published in April 2021, the U.S. Food and Drugs Administration (FDA) had approved 29 biosimilar drugs by 2020, and some of them were yet to be introduced in the market. Furthermore, an article by Generics and Biosimilars Initiative suggests, the entry of Amgen’s biosimilar Soliris was delayed till 2025. The outbreak of the COVID-19 pandemic had a negative impact on the global market. Since the supply chains of different products including pharmaceuticals were disrupted and most of the sources were dedicated to fighting COVID-19, the production of biosimilars experienced a shortage of raw materials.

For instance, according to a report published by Johns Hopkins Bloomberg School of Public Health, as a result of the lockdown, a shortage was observed in the supply of Active Pharmaceutical Ingredient (API), which is an important raw material used in producing drugs. These shortages directly affected the production and supply of biosimilars and other drugs during the pandemic. However, due to the increasing demand, several market players are significantly investing in the research & development of biosimilars, which can further add to the market growth. For instance, a key player offering advanced biotechnology solutions, Amgen Inc., has invested USD 2 billion in the development of 10 biosimilar medicines.

key Request a free sample copy or view report summary: Biosimilars Market Report

Biosimilars Market Report Highlights

Based on drug class, the monoclonal antibodies (mAbs) segment led the market with the largest revenue share of 44.98% in 2024, driven by increasing adoption of biosimilar mAbs in treating chronic diseases.
The autoimmune disorders (RA, IBD, psoriasis, and ankylosing spondylitis) segment led the market with the largest revenue share of 39.98% in 2024, driven by the growing prevalence of chronic inflammatory conditions.
The hospitals segment led the market with the largest revenue share of 52.09% in 2024, which can be attributed to high patient inflow and structured treatment protocols.
The oncology segment is expected to register the fastest CAGR of 19.36% during the forecast period due to the increasing prevalence of cancer and upcoming patent expiration for important biologics
In 2024, North America dominated the market with a share of 42.73% owing to the presence of several key players. On the other hand, Asia Pacific is anticipated to be the fastest-growing region at a CAGR of 19.67% over the forecast period due to new product launches and increasing healthcare expenditure